Phase 2, Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety/Pharmacokinetics of BMS-986142 in Subjects With Moderate to Severe Rheumatoid Arthritis With an Inadequate Response to Methotrexate With or Without TNF Inhibitors
Phase of Trial: Phase II
Latest Information Update: 09 Dec 2017
At a glance
- Drugs BMS 986142 (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 17 Oct 2017 Planned End Date changed from 30 Mar 2018 to 23 Apr 2018.
- 17 Oct 2017 Planned primary completion date changed from 29 Mar 2018 to 22 Apr 2018.
- 10 Jun 2017 Biomarkers information updated